Diabetologie 2007

Was ist neu?

• Leitlinien: Diabetes und Herz

• Prävention des Typ-2-Diabetes: Kein positiver Effekt durch ACE-Hemmer.

• Progressionshemmung des Typ-2-Diabetes: Die Ergebnisse von ADOPT

• Nutzen-Risiko-Bewertung: Herzinfarkt-Risiko und Rosiglitazon

• Neue Therapieansätze: GLP-1-Mimetika und DPP-4-Inhibitoren

• Gewichtsreduktion: Der Cannabinoid-Rezeptorantagonist Rimonabant

Literatur

• 1 Dormandy J A. et al . Secondary Prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study.  Lancet. 2005;  366 1279-1289
• 2 Drucker D, Nauck M A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.  Lancet. 2006;  368 1696-1705
• 3 Heart Outcomes Prevention Evaluation (HOPE) Study Investigators . Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO HOPE substudy.  Lancet. 2000;  355 253-259
• 4 Iranmanesh A, Rosenstock J. et al. on behalf of the SERENADE study group . SERENADE: Rimonabant monotherapy for treatment of multiple cardiometabolic risk factors in treatment-naïve patients with type 2 diabetes (Abstract 637b).  Diabetic Medicine. 2006;  23 (Suppl 4) 230
• 5 Kahn S E. et al . Glycemic durability of Rosiglitazone, Metformin, or Glyburide monotherapy.  N Engl J Med. 2006;  355 2427-2443
• 6 Nissen S E, Wolski K. Effect of Rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.  N Engl J Med. 2007;  356 ,  May 21 [Epub ahaed of print]
• 7 Scheen A J, Finer N. et al. . Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled trial.  Lancet. 2006;  368 1660-1672
• 8 Scherbaum W A. im Auftrag der DDG (Hrsg) . Praxis-Leitlinien der Deutschen Diabetes-Gesellschaft.  Diabetologie und Stoffwechsel. 2007;  (Suppl 2) 2 143-220
• 9 The DREAM (Diabetes REduction Assessment with amipril and rosiglitazone Medication) Trial Investigators . Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial.  Lancet. 2006;  368 1096-1105
• 10 The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) . Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary.  Eur Heart J. 2007;  28 88-136